← Oncology Approval Tracker

FDA DECISION ·

Gavreto

pralsetinib · Genentech

Traditional approvalTraditional conversionNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with metastatic NSCLC and an FDA test-confirmed RET fusion.

LAMPGEN ANALYSIS

Why it matters

The action converted the lung cancer accelerated approval to traditional approval.

What research teams should watch

Apply the conversion to the NSCLC indication and retain separate records for other RET-defined uses.

PRIMARY RECORDS

Sources